Alnylam Seeks To Advance RNAi Further With Inex Delivery Technology
This article was originally published in The Pink Sheet Daily
There is an "open invitation" to companies and academia to partner with Inex on RNAi therapies, Inex CEO tells "The Pink Sheet" DAILY.
You may also be interested in...
Alnylam predicts companies will come knocking on its door to license its intellectual property in the field.
Company looking to build on current deals with Merck and Novartis, COO says in interview with "The Pink Sheet" DAILY.
Previous spin-out Protiva has filed suit to stop the firm from moving almost all of its assets into a new company.